Pharma Industry News
Printable Version   Email to a friend

Topical Quinolone Antibiotics Outperform Systemics for Otitis Media

January 30, 2006

Topical Quinolone Antibiotics Outperform Systemics for Otitis Media

Topical quinolone antibiotics, such as Cipro (ciprofloxacin), treat ear infections with discharge more effectively than systemic antibiotics, according to a new report.

In a systematic review of randomized, controlled trials that compared use of topical antibiotics with systemic agents for chronic suppurative otitis media, topical quinolone antibiotics such as Cipro cleared aural discharge better than systemic antibiotic drugs.

Chronic suppurative ear infections can cause significant hearing loss.

The study was conducted by Carolyn MacFayden and colleagues of the International Health Research group at the Liverpool School of Tropical Medicine and reported in the online Cochrane Database of Systematic Reviews.

"Chronically discharging ears associated with underlying persistent eardrum perforations are a common cause of preventable hearing impairment worldwide, particularly in low and middle-income countries," MacFayden and colleagues wrote, reported MedPage Today.

"Chronic suppurative otitis media usually occurs in the first five years of life (although it often persists into adulthood), and is related to poor socioeconomic conditions."

Chronic suppurative otitis media is "a stage of ear disease in which there is chronic infection of the middle ear cleft, a non-intact tympanic membrane (i.e. perforated eardrum) and discharge otorrhea, for at least the preceding two weeks," according to the World Health Organization.

Data Analysis

The reviewers included in their analysis randomized, controlled trials comparing treatment of chronic suppurative otitis media with systemic therapy versus any topical treatment except steroids. Their goal was to determine the best treatment for chronically discharging ears with an underlying eardrum perforation.

Eight trials met the researchers' search criteria, although they noted that the definition and severity of chronic suppurative ear infections differed between the studies, and most of the studies reported less than two weeks of follow-up.

The data showed that, at 1-2 weeks, topical quinolones outperformed systemic antibiotics (both quinolone and non-quinolone agents) at clearing and drying the ears. Moreover, at 1-2 weeks, adding systemic drugs to topical agents offered no advantage, although evidence for this observation was limited.

Topical quinolones had a significant advantage over systemic non-quinolone agents and systemic quinolones. Also, combined topical and systemic quinolone (ciprofloxacin) were more effective than systemic quinolone alone.

"No statistically significant benefit was seen at two to four weeks for topical non-quinolone antibiotic (without steroids) or topical antiseptic over systemic antibiotics (mostly non-quinolones), but numbers were small," the authors noted, reported MedPage Today.

"Evidence regarding safety was generally weak. Adverse events reported were generally mild, although hearing worsened by ototoxicity (damaging auditory hair cells) was seen with chloramphenicol drops (non-quinolone antibiotic)," the researchers wrote.

Sources:
Topical Antibiotics Beat Systemics for Clearing Suppurative Otitis Media, MedPage Today, January 25, 2006.
Systemic antibiotics versus topical treatments for chronically discharging ears with underlying eardrum perforations. Macfadyen CA, Acuin JM, Gamble C, The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005608. DOI: 10.1002/14651858.CD005608.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
October 9, 2008
Audience: Pediatric and primary healthcare professionals, consumers [Posted 10/09/2008] FDA notified healthcare professionals and...
October 7, 2008
Audience: Pulmonary care health professionals and patients[UPDATE 10/07/2008] FDA informed healthcare professionals that FDA has...
October 3, 2008
Audience: Healthcare professionals, consumers [Posted 10/03/2008] FDA notified healthcare professionals of a Class I Recall of...
October 2, 2008
Audience: Physical medicine and rehabilitation specialists, anesthesia healthcare professionals, hospital surgical service...
More...
Latest Drug Information Updates

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

More...